TITLE

Pharma Steps Up to Help With Swine Flu

PUB. DATE
June 2009
SOURCE
Pharmaceutical Representative;Jun2009, Vol. 39 Issue 6, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the move by the pharmaceutical companies Roche and GlaxoSmithKline (GSK) to work with the U.S. government to provide medication to the people most affected by swine influenza. While Roche has pointed out the significance of its drug Tamiflu for the disease, GSK has supplied 100,000 packs of its antiviral Relenza to Mexico along with 170,000 doses of its seasonal vaccine for the flu. Both Tamiflu and Relenza are reportedly found to be effective in treating swine influenza.
ACCESSION #
40521958

 

Related Articles

  • FLU'S UNEXPECTED BONUS. Jack, Andrew // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/26/2009, Vol. 339 Issue 7723, p720 

    The article investigates the financial effects of the 2009 H1N1 pandemic flu on drug manufacturers and biotechnology companies in the U.S. Biotechnology company Gilead Sciences Inc. made 52 million U.S. dollars in royalties for its antiviral medicine oseltamivir or Tamiflu in the three months...

  • Cipla plans to sell generic Tamiflu.  // TCE: The Chemical Engineer;Jun2009, Issue 816, p12 

    The article reports on the agreement of Cipla, an India-based producer of low cost and generic pharmaceuticals, to produce and sell large quantities of Antiflu, the generic version of the antiviral drug Tamiflu, as part of an effort to combat swine flu in Mexico. According to Cipla, it will only...

  • How soon until a swine flu vaccine? Ryan, Jeff; Skernivitz, Stephanie // Contemporary Pediatrics;Jun2009, Vol. 26 Issue 6, p24 

    The article assesses the possibility of having vaccines for influenza H1N1. It cites the order by the World Health Organization (WHO) for pharmaceutical companies to prepare to make a possible pandemic level of swine flu doses, which would be about two billion doses. According to the article,...

  • New routes to bird flu drug.  // Pharmaceutical Technology Europe;Jun2006, Vol. 18 Issue 6, p10 

    The article reports that some individuals are stockpiling Roche's antiviral compound called Tamiflu because of concerns about the H5N1 strain of the avian influenza virus. The demand for Tamiflu is higher than supply and there is a fear that the supply chain wuld be unable to coped with the...

  • Neuraminidase inhibitors: the story behind the Cochrane review. Doshi, Peter // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;12/12/2009, Vol. 339 Issue 7734, p1348 

    The article explores the inconsistent and fragmented evidence for the use of the global public health drug oseltamivir from Roche for pandemic influenza as discovered by the team updating the Cochrane review of neuraminidase inhibitors. A review of neuraminidase inhibitors was commissioned by...

  • What can we learn from observational studies of oseltamivir to treat influenza in healthy adults? Freemantle, Nick; Calvert, Mel // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;12/12/2009, Vol. 339 Issue 7734, p1352 

    The article investigates the limited value of studies of the use of the antiviral drug oseltamivir to treat influenza in healthy adults identified by Roche. It discusses the problems associated with randomised controlled trials as a basis for examining the effects of the drug. It examines the...

  • News in Brief.  // Nature Reviews Drug Discovery;Jun2009, Vol. 8 Issue 6, p441 

    The article presents news briefs related to drug discoveries in the pharmaceutical industry. Roche Holding AG and the company GlaxoSmithKline are manufacturing new antiviral drugs for the recent swine flu pandemic and developing vaccine manufacturing facilities for it with the use of latest...

  • Big Paydays for H1N1 Vaccine Makers.  // Pharmaceutical Representative;Sep2009, Vol. 39 Issue 9, p8 

    The article reports on the speculation concerning the growth in revenues to be generated by pharmaceutical companies brought by the increase in demand for swine flu vaccines. GlaxoSmithKline anticipates to generate two billion dollars in sales for its vaccines in 2010. Meanwhile, Roche Holding...

  • Pharma Acts on Swine Flu.  // Pharmaceutical Executive;May2009, Vol. 29 Issue 5, p13 

    The article reports on the move of the pharmaceutical industry to lessen the spread of swine flu in the U.S. As stated, swine flu can be treated with two existing antiviral treatments such as Relenza from GlaxoSmithKline and Tamiflu by Roche/Gilead. With regards to the attack of the virus, the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics